24 Feb 2026
The first patients have been treated with a monoclonal amyloid antibody at the hospital. The indication includes patients with Alzheimer's disease in the stage of mild cognitive impairment (MCI) or mild dementia.
Alzheimer's disease is the most common cause of neurodegenerative dementia and poses major challenges for those affected and their families. With the recently approved antibody therapies, a treatment is now available for the first time that directly targets the underlying mechanisms of the disease.
Amyloid antibodies specifically target the disease-causing amyloid deposits in the brain, which are considered a key factor in the development of Alzheimer's disease. The breakdown of these deposits can slow down the disease in selected patients in the early stages of the disease, thereby slowing down the loss of cognitive function.
In addition to Alzheimer's disease confirmed by amyloid detection, comprehensive diagnostics including neuropsychological testing as well as imaging and genetic diagnostics are prerequisites for therapy.
Treatment is provided as part of a structured therapy concept involving close interdisciplinary cooperation between the departments of neurology, psychiatry, neuroradiology/radiology, and nuclear medicine. This includes comprehensive information, regular clinical check-ups, and imaging follow-up examinations. Therapy is only carried out on carefully selected patients and is based on the latest scientific findings and national and international guidelines.
LMU Medical Center PD Dr. med. Sonja Schönecker, Department of Neurology and Polyclinic | © LMU Klinikum
For the first time, we have access to a disease-modifying treatment that specifically targets the underlying processes of Alzheimer's disease. This requires careful and early diagnosis in order to identify suitable patients. As a university center, we combine clinical expertise, modern biomarker diagnostics, and structured follow-up checks to ensure the responsible use of these innovative therapies based on the latest medical and scientific knowledge."
PD Dr. med. Katharina Bürger, Institut für Schlaganfall- und Demenzforschung (ISD) | © LMU Klinikum
“We are pleased that our patients finally have access to the new therapies, albeit to a limited extent. The medical criteria for this therapy are strictly regulated, and the complexity of this infusion therapy is considerable. For eligible patients, we can now offer another therapeutic option for early-stage Alzheimer's disease at the university level.”
Prof. Robert Perneczky, MD, Department of Psychiatry and Psychotherapy | © LMU Klinikum
“From the perspective of the psychiatric clinic, the first-time use of amyloid antibody therapy represents an important step in the further development of treatment for people with Alzheimer's disease. The close interdisciplinary exchange between the departments of neurology, nuclear medicine, psychiatry, and radiology is particularly valuable in this regard, as it ensures optimal care for patients.”
With the introduction of this therapy, LMU Hospital is expanding its range of services in the field of neurodegenerative diseases and underlining its commitment to offering modern, evidence-based medicine of the highest standard. At the same time, the hospital is making an important contribution to the further development of regional care for people with dementia.